Patents Examined by Padma Baskar
-
Patent number: 8246964Abstract: Antigenic protein fragments of Streptococcus pneumoniae to be used for the preparation of a medicament for the prevention and the treatment of bacterial infections and a method for the detection thereof, and related compositions using said epitopes, are disclosed.Type: GrantFiled: March 17, 2009Date of Patent: August 21, 2012Assignees: Universita' Degli Studi di SienaInventors: Concetta Beninati, Franco Felici, Marco Oggioni, Gianni Pozzi, Susanna Ricci
-
Patent number: 8241643Abstract: The present invention relates to a protective peptide of Streptococcus pneumoniae (S. pneumoniae) or a functionally active variant thereof; a composition comprising at least two of such peptides or variants; one or more nucleic acid(s) encoding such peptide or variant; a pharmaceutical composition comprising such peptide or variant, composition, or nucleic acid(s); a method of producing an antibody using such peptide or variant or composition; the use of such peptide or variant and/or composition and/or nucleic acid(s) for the manufacture of a medicament; a method of diagnosing a S. pneumoniae infection using such peptide or variant, composition or a primer and/or probe specific for the nucleic acid(s); a method for identifying a ligand capable of binding to such peptide or variant; and the use of such peptide or variant for the isolation, purification and/or identification of an interaction partner of the peptide.Type: GrantFiled: March 17, 2009Date of Patent: August 14, 2012Assignee: Intercell AGInventors: Andreas Meinke, Astrid Teubenbacher, Beatrice Senn, Manuel Zerbs, Markus Hanner, Jutta Pikalo, Eszter Nagy, Carmen Giefing-Krōll, Alexander Von Gabain
-
Patent number: 8241611Abstract: The invention provides a method of preventing, inhibiting or reducing a P. gingivalis biofilm in a subject comprising administering to the subject a pharmaceutical composition comprising an inhibiting agent of a polypeptide that reduces or inhibits biofilm formation and/or biofilm development. Also provided are compositions useful in the prevention, inhibition or treatment of periodontal disease or P. gingivalis infection.Type: GrantFiled: July 11, 2008Date of Patent: August 14, 2012Assignee: Oral Health Austrailia Pty. Ltd.Inventors: Stuart Geoffrey Dashper, Eric Charles Reynolds, Paul David Veith, Ching Seng Ang
-
Patent number: 8241642Abstract: The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of Streptococcus pneumoniae, wherein the open reading frames encode polypeptides that are surface localized on Streptococcus pneumoniae. Thus, the invention relates to Streptococcus pneumoniae open reading frames that encode polypeptide antigens, polypeptides, preferably antigenic polypeptides, encoded by the Streptococcus pneumoniae open reading frames, vectors comprising open reading frame sequences and cells or animals transformed with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Streptococcus pneumoniae infection. The invention finally relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with Streptococcus pneumoniae.Type: GrantFiled: May 12, 2010Date of Patent: August 14, 2012Assignee: Wyeth Holdings CorporationInventors: Robert John Zagursky, Amy Wadhams Masi, Bruce Arthur Green, Deb Narayan Chakravarti, David Parrish Russell, Joseph Lawrence Wooters
-
Patent number: 8236932Abstract: This invention provides antibodies that specifically bind and neutralize Staphylococcus enterotoxin B. In addition, nucleic acids encoding such antibodies, and cells that express such antibodies are provided. Also provided are methods for treating diseases mediated by, and for neutralizing Staphylococcus enterotoxin B.Type: GrantFiled: January 3, 2008Date of Patent: August 7, 2012Assignee: Morphotek, Inc.Inventors: Philip M. Sass, Nicholas C. Nicolaides, Luigi Grasso, Marc Berger, Tao Sai
-
Patent number: 8236325Abstract: Hyperimmune serum reactive antigens and fragments thereof are disclosed. In addition, methods for isolating such antigens and specific uses thereof, including the treatment of S. epidermidis infections, are disclosed.Type: GrantFiled: November 24, 2009Date of Patent: August 7, 2012Assignee: Intercell AGInventors: Andreas Meinke, Duc Min Bui, Eszter Nagy
-
Patent number: 8236326Abstract: The present invention relates to isolated nucleic acid molecules which encode an antigen, a vector which comprises such nucleic acid molecule, and a host cell comprising such vector. Furthermore, the invention provides antigens from a Klebsiella species, as well as fragments and variants thereof, a process for producing such antigens, and a process for producing a cell, which expresses such antigen. Moreover, the present invention provides antibodies binding to such antigen, a hybridoma cell producing such antibodies, methods for producing such antibodies, a pharmaceutical composition comprising such nucleic acid molecule, antigen, vector or antibody, the use of such nucleic acid molecule, antigen, vector or antibody for the preparation of a pharmaceutical composition, methods for identifying an antagonist capable of binding such antigen or of reducing or inhibiting the interaction activity of such antigen, methods for diagnosing an infection and methods for the treatment or prevention of an infection.Type: GrantFiled: April 29, 2008Date of Patent: August 7, 2012Assignee: Intercell AGInventors: Sharmila Bakshi, Thomas Cipps, Markus Hanner, Jutta Pikalo, Christina Satke, Eszter Nagy, Urban Lundberg, Dagmar Zierer, Andreas Meinke, Birgit Noiges, Ulrike Stierschneider, Alexander von Gabain
-
Patent number: 8231881Abstract: The present invention relates generally to a fusion protein made from a synthetic gene construct comprising of elements derived from the Leishmania antigens K26, K39, and K9. The fusion protein is particularly useful in the diagnosis of leishmaniasis, particularly visceral leishmaniasis in animals such as humans and dogs.Type: GrantFiled: July 2, 2009Date of Patent: July 31, 2012Assignee: Infectious Disease Research InstituteInventors: Ajay Bhatia, Steven G. Reed
-
Patent number: 8226960Abstract: NMB1870 is a protein in Neisseria meningitidis. Three families of NMB1870 are known. To increase the ability of a NMB1870 protein to elicit antibodies that are cross-reactive between the families, NMB1870 is engineered. Sequences can be substituted from one NMB1870 family into the corresponding position in another family. Proteins of NMB1870 sequences from different families can be joined to each other.Type: GrantFiled: November 27, 2006Date of Patent: July 24, 2012Assignee: Novartis AGInventors: Vega Masignani, Maria Scarselli, Rino Rappuoli, Mariagrazia Pizza, Marzia Monica Giuliani
-
Patent number: 8217159Abstract: The invention provides BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and polynucleotides encoding BASB082, BASB083, BASB091, BASB092 and BASB101 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: January 8, 2010Date of Patent: July 10, 2012Assignee: GlaxoSmithKline Biologicals S.A.Inventors: Catherine Defrenne, Christine Delmelle, Jean-Louis Ruelle
-
Patent number: 8211447Abstract: In this application is described the expression and purification of a recombinant Plasmodium falciparum (FVO) MSP-142. The method of the present invention produces a highly purified protein that retains folding and disulfide bridging of the native molecule. The recombinant MSP-142 is useful as a diagnostic reagent, for use in antibody production, and as a vaccine.Type: GrantFiled: July 21, 2009Date of Patent: July 3, 2012Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Evelina Angov, Jeffrey A. Lyon, Christian Asare Darko, Joe D. Cohen
-
Patent number: 8178310Abstract: Disclosed are the cloning and expression of novel antigens in Babesia microti. The recombinant polypeptides are highly immunogenic. The polypeptides of the present invention provide the basis of a diagnostic assay that is sensitive, rapid and accurate using patient's sera. Also disclosed is an IgG and IgM ELISA using two novel recombinant antigens in the diagnosis of Babesia infection.Type: GrantFiled: April 14, 2009Date of Patent: May 15, 2012Assignee: Medical Diagnostic Laboratories, LLCInventors: John G. Hoey, Hannah Venit, Martin E. Adelson, Eli Mordechai, Fernando Valois-Cruz
-
Patent number: 8168167Abstract: The invention relates to a method for biologically combating the proliferation of Legionella pneumophila, with the exception of the treatment methods applied to the human or animal body, characterized in that it uses amoebic protozoa of the species Willaerita magna, corresponding to the strain deposited with the ATCC under number PTA-7824 or the strain deposited with the ATCC under number PTA-7825.Type: GrantFiled: October 12, 2007Date of Patent: May 1, 2012Assignee: Universite Claude Bernard Lyon IInventors: Jacques Bodennec, Rafik Dey, Pierre Pernin
-
Patent number: 8163288Abstract: The invention relates to antigenic polypeptides expressed by pathogenic microbes, vaccines comprising said polypeptides; therapeutic antibodies directed to said polypeptides and methods to manufacture said polypeptides, vaccines and antibodies.Type: GrantFiled: June 29, 2010Date of Patent: April 24, 2012Assignee: Absynth Biologics LimitedInventors: Simon J. Foster, Jorge Garcia-Lara
-
Patent number: 8147849Abstract: The invention provides protective antigens for Group B streptococcus hypervirulent strains. The fragments are useful in vaccine compositions to induce protection against S. agalactiae, particularly against hypervirulent strains.Type: GrantFiled: February 16, 2010Date of Patent: April 3, 2012Assignee: Novartis AGInventors: Francesco Doro, Nathalie Norais, Domenico Maione, Sabrina Liberatori, Guido Grandi
-
Patent number: 8143024Abstract: The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of Chlamydia trachomatis, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of the Chlamydia trachomatis genome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosing Chlamydia trachomatis infection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides.Type: GrantFiled: February 28, 2011Date of Patent: March 27, 2012Assignee: Merck Serono BiodevelopmentInventors: Rémy Griffais, Susan K. Hoiseth, Robert J. Zagursky, Benjamin J. Metcalf, Joel A. Peek, Banumathi Sankaran, Leah D. Fletcher
-
Patent number: 8138316Abstract: Isolated nucleic acid molecules having a nucleotide sequence encoding feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Isolated feline pancreatic lipase polypeptides, splice variants, allelic variants, and fragments thereof. Host cells comprising a vector containing the polynucleotide sequences and methods for expressing the polypeptides. The generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies. Methods for determining the presence or amount of feline pancreatic lipase in a biological sample. The methods include using standards or calibrators of recombinant feline pancreatic lipase to quantify the lipase in a sample. Devices and kits for performing methods for detecting feline pancreatic lipase in biological samples.Type: GrantFiled: June 10, 2010Date of Patent: March 20, 2012Assignee: IDEXX Laboratories, Inc.Inventors: Philip Andersen, Melissa Jane Beall, Jesse Buch, Ku-chuan Hsiao, Stacey Pazar Huth, Eugene Regis Krah, III, Barbara O'Brien, Marilyn Strong-Townsend
-
Patent number: 8137678Abstract: The present invention provides a vaccine for canine Lyme disease and methods of making and using the vaccine alone, or in combinations with other protective agents.Type: GrantFiled: November 1, 2007Date of Patent: March 20, 2012Assignee: Intervet Inc.Inventors: Steven M. Callister, Rhonda LaFleur, Terri L. Wasmoen
-
Patent number: 8133973Abstract: The present invention provides variant LcrE sequences and/or combinations of variant LcrE sequences across the Chlamydia trachomatis serovars. Such changes in LcrE genotypes across the Chlamydia trachomatis serovars are likely to correspond with changes in LcrE phenotypes, in particular, with changes in immunogenicity. The present invention also provides peptides surrounding or associated with the amino acid substitutions, in particular, peptides surrounding or associated with high frequency mutated amino acid positions or hypervariable regions, which are likely to be B and/or T cell epitopic regions capable of eliciting Chlamydia specific cell mediated immune responses. The variant LcrE sequences and/or combinations of the variant LcrE sequences and/or epitope regions associated with the variant LcrE sequences are useful as immunogens and/or in the preparation of immunogenic compositions for preventing and/or treating and/or, diagnosing Chlamydia infections.Type: GrantFiled: May 12, 2006Date of Patent: March 13, 2012Assignee: Novartis Vaccines and Diagnostics, S.r.l.Inventors: Guido Grandi, Giulio Ratti
-
Patent number: 8129165Abstract: The present invention relates to isolated nucleic acid molecules which encode a protein, isolated nucleic acid molecules which encode a hyperimmune serum reactive antigen, a vector which comprises such nucleic acid molecule, a host cell comprising such vector, a hyperimmune reactive antigen from Borrelia species, proteins which are preferably hyperimmune serum reactive antigens, hyperimmune serum reactive antigens, antigens, a process for producing such proteins, hyperimmune serum reactive antigens or antigens, a process for producing a cell which expresses such protein, hyperimmune serum reactive antigen or antigen, an antibody binding to such protein, hyperimmune serum reactive antigen or antigen, a hybridoma cell producing such antibody, methods for producing such antibody, a pharmaceutical composition comprising such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibody, the use of such nucleic acid molecule, protein, hyperimmune serum reactive antigen, antigen or antibodType: GrantFiled: September 14, 2007Date of Patent: March 6, 2012Assignee: Intercell AGInventors: Urban Lundberg, Andreas Meinke, Eszter Nagy, Alexander von Gabain, Birgit Noiges, Dieter Gelbmann, Albina Poljak, Christine Triska